Katherine C Fuh1, Angeles A Secord2, Kerri S Bevis3, Warner Huh3, Adam ElNaggar4, Kevin Blansit5, Rebecca Previs2, Todd Tillmanns4, Daniel S Kapp6, John K Chan7. 1. Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University Of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1702, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, School of Medicine, St. Louis, MO 63108, United States; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University, School of Medicine, 400 Pasteur Drive, Stanford, CA 94305, United States. 2. Division of Gynecologic Oncology, Department Of Obstetrics and Gynecology, Duke University, School Of Medicine, DUMC 3079, Durham, NC 27710, United States. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, 1700 6th Ave South, Birmingham, AL 35233, United States. 4. The West Clinic, University of Tennessee, 100N. Humphreys Blvd, Memphis, TN 38120, United States. 5. Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University Of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1702, United States; Palo Alto Medical Foundation Research Institute, 795 El Camino Real, Ames Building, Palo Alto, CA 94301, United States. 6. Department of Radiation Oncology, Department of Obstetrics and Gynecology, Stanford University, School of Medicine, 400 Pasteur Drive, Stanford, CA 94305, United States. 7. Division of Gynecologic Oncology, Helen Diller Family Comprehensive Cancer Center, University Of California, San Francisco, 1600 Divisadero Street, San Francisco, CA 94143-1702, United States; Palo Alto Medical Foundation Research Institute, 795 El Camino Real, Ames Building, Palo Alto, CA 94301, United States. Electronic address: chanjohn@sutterhealth.org.
Abstract
BACKGROUND: To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS: A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. RESULTS: Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group. CONCLUSION: This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.
BACKGROUND: To compare the efficacy of chemotherapy (C) combined with bevacizumab (Bev) versus Bev alone in recurrent, heavily pretreated epithelial ovarian cancer (EOC). METHODS: A multicenter analysis of patients treated from 2004 to 2011 was performed. Demographic, treatment, response, and adverse event information were obtained. Progression-free (PFS) and overall survival (OS) were analyzed. RESULTS: Of 277 patients (median age: 58years), the majority had Stage III and IV (86%) disease, and 72% had serous histology. 244 (88%) were treated with C+Bev and 33 (12%) with Bev. Corresponding median progression-free survival (PFS) was 8.7 and 6.7months, and median overall survival (OS) was 14.3 and 10.5months, respectively. The chemotherapeutic agents combined with Bev and the median OS include: pegylated liposomal doxorubicin (n=19, OS of 20.4months), taxanes (n=55, OS of 20.2months), gemcitabine (n=106, OS of 14.1months), topotecan (n=43, OS of 13months), and cyclophosphamide (n=21, OS of 13months). There was no significant difference in toxicities between the C+Bev vs. Bev alone group. CONCLUSION: This retrospective analysis supports that combination chemotherapy and bevacizumab prolongs PFS and OS compared with bevacizumab alone.
Authors: John K Chan; William Brady; Bradley J Monk; Jubilee Brown; Mark S Shahin; Peter G Rose; Jae-Hoon Kim; Angeles Alvarez Secord; Joan L Walker; David M Gershenson Journal: Gynecol Oncol Date: 2018-06-18 Impact factor: 5.482
Authors: John K Chan; Stephanie Chow; Subasish Bhowmik; Amandeep Mann; Daniel S Kapp; Robert L Coleman Journal: Clin Exp Metastasis Date: 2018-06-21 Impact factor: 5.150
Authors: Andreas Heinzel; Maximilian Marhold; Paul Mayer; Michael Schwarz; Erwin Tomasich; Arno Lukas; Michael Krainer; Paul Perco Journal: PLoS One Date: 2019-01-25 Impact factor: 3.240